Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

share with twitter share with LinkedIn share with facebook
04/22/2013 | 01:09am EDT


Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN

and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur.

"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."

Key benefits of HexyonTM/Hexacima® vaccine:

share with twitter share with LinkedIn share with facebook
All news about SANOFI
08/13EU to enter contract talks with J&J over 200 million doses of potential COVID..
08/12SANOFI : Solicitor Representing Sodium Valproate Patient Groups Comments On Sano..
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
08/05U.S. to pay $1 billion for 100 million doses of J&J's COVID-19 vaccine candid..
08/05Regeneron 2Q Profit Surges on Collaborations
08/05Regeneron profit beats, expects early results from COVID-19 trials in Septemb..
08/05COVID-19 VACCINE TRIALS HAVE A PROBL : Minority Groups Don't Trust Them
08/03SANOFI : Credit Suisse reaffirms its Buy rating
More news
Sales 2020 37 030 M 43 730 M 43 730 M
Net income 2020 11 769 M 13 898 M 13 898 M
Net Debt 2020 6 792 M 8 021 M 8 021 M
P/E ratio 2020 9,43x
Yield 2020 3,67%
Capitalization 109 B 129 B 129 B
EV / Sales 2020 3,13x
EV / Sales 2021 2,89x
Nbr of Employees 100 409
Free-Float 88,9%
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104,85 €
Last Close Price 86,99 €
Spread / Highest target 41,2%
Spread / Average Target 20,5%
Spread / Lowest Target -2,29%
EPS Revisions
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.93%129 276
JOHNSON & JOHNSON1.46%394 028
ROCHE HOLDING AG1.08%297 694
PFIZER, INC.-2.58%212 995
MERCK & CO., INC.-8.15%209 118
NOVARTIS AG-15.76%187 147